Latest Australian Market News

Live Verdure Ltd has secured a controlling stake in AI innovator Decidr.ai and reported robust e-commerce growth for its Edible Beauty brand, underscoring its strategic pivot towards AI-driven expansion.

Aeeris Ltd reported solid growth in Q2 FY25, driven by increased annual recurring revenue and new contracts across key sectors, while unveiling a promising new technology set to expand its market footprint.

EVE Health Group has completed the sale of its Robyndale tea tree property and relaunched its postbiotic concentrate range, signaling a strategic shift towards innovation and growth in the Australian market.

Airtasker Limited reported a robust second quarter with marketplaces revenue up 15.8%, driven by explosive growth in the UK and US, alongside positive free cash flow of $0.5 million. The company’s strategic media partnerships underpin its international expansion ambitions.

Microba Life Sciences reports a remarkable 102% revenue increase in Q2 FY25, driven by strong sales of its MetaXplore test in Australia and promising early traction in the UK. The company also advances its therapeutic pipeline with key clinical milestones.

4DMedical reports a remarkable 202% increase in Q2 FY2025 operating revenue, driven by rapid site expansion and key collaborations with leading healthcare providers and the U.S. Department of Defense.

OncoSil Medical has achieved a key regulatory milestone with MDR certification from BSI, removing post-market restrictions and streamlining its commercial operations across Europe. This approval also paves the way for renewed efforts to enter the Australian market.

Pureprofile Limited has upgraded its FY25 financial guidance following a robust first half, highlighted by a 22% revenue increase and a 30% surge in Q2, driven by strong international expansion and automation adoption.

4DMedical has signed a landmark commercial agreement with Qscan Radiology Clinics, marking its first Australian contract to integrate both Pulmonary Function and Pulmonary Structure imaging products.

RLF AgTech Ltd has retracted previously announced field trial results due to ASX compliance issues, while simultaneously reporting significant debt reduction and ongoing equity raising efforts to support its expanding Australian and Chinese operations.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.

Leo Lithium Limited has announced a total distribution of 17.2 cents per share, combining a capital return and a special dividend, payable at the end of January 2025.